# DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES

> **NIH NIH N01** · CUBRC, INC. · 2022 · $71,282

## Abstract

This contract supports the advanced development of promising biodefense therapeutic candidates/products with broad spectrum activity. The research and development activities supported will allow candidate therapeutic countermeasures to progress through the product development pipeline, and includes preclinical/non-clinical and clinical IND translational development activities.

## Key facts

- **NIH application ID:** 10551002
- **Project number:** 272201100028C-P00036-9999-2
- **Recipient organization:** CUBRC, INC.
- **Principal Investigator:** Anne Kathleen Radcliff
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $71,282
- **Award type:** —
- **Project period:** 2011-09-30 → 2021-12-13

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10551002

## Citation

> US National Institutes of Health, RePORTER application 10551002, DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES (272201100028C-P00036-9999-2). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10551002. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*